Education and Experience
- University of Wales (CARDIFF )/ (2003)
- Johns Hopkins Bayview Medical Center (Baltimore MD)/ Medicine/General Internal Medicine (2007)
- The Johns Hopkins Hospital (Baltimore MD)/ Oncology (2010)
- Medical Oncology, American Board of Internal Medicine (2009)
- Internal Medicine, American Board of Internal Medicine (2007)
- Brady Urological Institute
- Prostate Cancer Multidisciplinary Clinic
- Sidney Kimmel Comprehensive Cancer Center
His research focuses primarily on GU cancers, with a particular emphasis on prostate cancer, clinical trial development, and immunotherapy. As a clinical investigator with a priority on translational drug development, Dr Antonarakis uses prognostic models of prostate cancer progression to design more informative and personalized clinical trials in men with localized or early relapsed prostate cancer, including validating much needed clinical trial endpoints unique to prostate cancer. He currently serves as Principal Investigator on several clinical trials available to patients at the Kimmel Cancer Center.
- Bladder Cancer
- General Internal Medicine
- Kidney Cancer
- Prostate Cancer
- Testicular Cancer
- Urological Oncology
Dr. Antonarakis is an Assistant Professor of Oncology with an interest in genitourinary cancers and a particular focus on prostate cancer. He is an expert in the clinical management of patients with prostate cancer, kidney cancer, testicular cancer, bladder cancer, and other urological malignancies.
His principal research activities consist of designing and conducting clinical trials that test investigational new drugs in the treatment of prostate cancer. More specifically, he is interested in expanding treatment options for men with early prostate cancer who experience a recurrence of their disease (evidenced only by a rising PSA level) after prostate surgery or radiotherapy. In addition, he is interested in testing immunological therapies (e.g. cancer vaccines) in the treatment of prostate cancer. As a clinical investigator with a priority on translational drug development, he plans to use prognostic models of prostate cancer progression to design more informative and tailored clinical trials, and to validate clinical trial endpoints that are unique to prostate cancer.
Antonarakis, E.S.; Blackford, A.L.; Garrett-Mayer, E.; Eisenberger, M.A. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol. 2007 Nov 1;25(31):4998-5008.
Antonarakis, E.S.; Eisenberger, M.A. Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer? Nature clinical practice. 2008 Sep;5(9):480-481.
Antonarakis, E.S.; Eisenberger, M.A. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? Nature clinical practice. 2009 Jan;6(1):12-13.
Antonarakis, E.S.; Heath, E.I.; Walczak, J.R.; Nelson, W.G.; Fedor, H.; De Marzo, A.M.; Zahurak, M.L.; Piantadosi, S.; Dannenberg, A.J.; Gurganus, R.T.; Baker, S.D.; Parnes, H.L.; DeWeese, T.L.; Partin, A.W.; Carducci, M.A. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol. 2009 Oct 20;27(30):4986-4993.
Antonarakis, E.S.; Carducci, M.A. Future directions in castrate-resistant prostate cancer therapy. Clin Genitourin Cancer. 2010 Dec 1;8(1):37-46.
Antonarakis, E.S.; Carducci, M.A. Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects. Expert Opin Investig Drugs. 2010 Feb;19(2):311-314.
Antonarakis, E.S.; Carducci, M.A.; Eisenberger, M.A. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 2010 May 1;291(1):1-13.
Antonarakis, E.S.; Chen, Y.; Elsamanoudi, S.I.; Brassell, S.A.; Da Rocha, M.V.; Eisenberger, M.A.; McLeod, D.G. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int. 2010 Nov 23.
Antonarakis, E.S.; Drake, C.G. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010 May;20(3):241-246.
Antonarakis, E.S.; Emadi, A. Ruthenium-based chemotherapeutics: are they ready for prime time? Cancer Chemother Pharmacol. 2010 May;66(1):1-9.
Drake, C.G.; Antonarakis, E.S. Update: immunological strategies for prostate cancer. Curr Urol Rep. 2010 May;11(3):202-207.
Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010 Nov 1;16(21):5269-5276.
- Prostate Cancer
- Prostate Cancer